Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Share:
Related RGEN
Events for the Week of Nov. 17-21, 2014
Regeneron Genetics Center Fully Operational, Announces New Collaborations And Key Appointments
Related PFE
Fast Money Picks For August 3
Mid-Day Market Update: Friday's Top 10 Volume Stocks
Healthcare: 9.6% More Net Gains From 5 Highest Yield, Lowest Priced July 29 Dogs (Seeking Alpha)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

Get Benzinga's Newsletters